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COVID-19, the multifactorial disease caused by the novel coronavirus SARS-CoV-2 is mediated by specific antiviral 
and inflammatory responses. It is now recognized that in most severe cases of COVID-19 an excessive and uncontrolled 
inflammatory response exacerbates lung damage caused by viral infection, and contributes to acute respiratory distress 
syndrome and respiratory failure. This hyperinflammatory syndrome is characterized by multiple cellular and molecular 
events, including aberrant neutrophil and lymphocyte function, amplification of the inflammatory response by release of 
damage associated molecular patterns, cytokine storm, lung damage and edema and a pro-fibrotic condition, ultimately 
leading to respiratory failure. This review discusses these molecular events in correlation with stages of viral infection and 
disease progression, underscoring the key points that characterize the clinical manifestations of the hyperinflammatory 
syndrome in COVID-19. Furthermore, it discusses the available or potential therapeutics that target various important 
mediators of this hyperinflammatory response that are being considered for treatment of COVID-19. 
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Introduction 
In the eight months since the first cases of Severe 
Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) infection were reported from China in 
December 2019, the virus has caused a worldwide 
pandemic infecting more than 23 million people and 
causing more than 800, 000 deaths (https://coronavirus. 
jhu.edu/map.html). The epidemiology of COVID-19, 
the disease caused by SARS-CoV-2, differs from the 
earlier coronavirus-induced diseases caused by Severe 
Acute Respiratory Syndrome Coronavirus (SARS-
CoV) and Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV) due to its greater 
transmission, resulting in a much larger number of 
people getting infected. Although the proportion of 
patients progressing to severe disease is less for SARS-
CoV-2 than SARS-CoV or MERS-CoV, the vastly 
higher number of infections has caused greater number 
of patients with severe acute respiratory distress 
requiring intensive care and ultimately in much higher 
number of deaths. Understanding the characteristics of 
COVID-19, both in terms of the viral infection as well 
as the host response to the virus is crucial for 
developing effective therapeutic strategies to combat 
the multistage progression of the disease
1
. 
SARS-CoV-2 infects pneumocytes lining the alveoli 
of lungs through interaction of its spike (S) protein 
with angiotensinogen converting enzyme 2 (ACE2) 
expressed on cell surfaces and penetrates host cells on 
activation of the cellular transmembrane protease 
serine 2 (TMPS2)
2,3
. The destruction of the alveolar 
cells leads to atypical pneumonia progressing to acute 
lung injury and acute respiratory distress syndrome 
(ARDS) in many patients
4,5
. While most individuals 
with SARS-CoV-2 pneumonia clears the lung infection 
via host immune responses, resulting in mild or no 
symptoms, in most severe cases an aggressive and 
uncontrolled inflammatory response exacerbates the 
lung damage and can lead to respiratory failure. 
Therefore it is increasingly becoming apparent that 
disease severity in COVID-19 is related not only to 
alveolar cell damage caused by SARS-CoV-2 but also 
to a hyperinflammatory syndrome that leads to lung 
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the molecular and cellular basis of this hyperin- 
flammatory response is therefore of critical importance 
for deciding the course of treatment for COVID-19 
patients with severe disease. 
 
Hyperinflammatory response and COVID-19 pathology 
Inflammation is the primary protective response of 
the body to any infection or injury. However, 
inflammation is a double-edged sword as 
hyperactivation of the inflammatory response can lead to 
aberrant activation of inflammatory cells and protracted 
release of inflammatory mediators such as cytokines and 
chemokines
7
. The acute and protracted release of 
cytokines, referred to as ―cytokine storm‖ or cytokine 
release syndrome (CRS) and aberrant activation of 
inflammatory cells such as neutrophils and monocytes 
cause host tissue damage, leading to morbidity and 
mortality
8
. Several studies have shown that COVID-19 
is marked by a virus-induced shift from a protective 
antiviral immunity to a hyperinflammatory response 
observed in critically ill COVID-19 patients, as has been 
observed previously in SARS-CoV and MERS-CoV 
infections
9–11
. (Fig. 1) However, the role of infiltrating 
and peripheral immune cells in COVID-19 lung injury, 
 
 
Fig. 1 — Course of viral infection and host immune response in COVID-19 hyperinflammatory syndrome. SARS-CoV-2 enters lung 
epithelial cells via interaction with cell surface proteins ACE2 and TMPS2. After endocytosis, the viral genomic (+ve strand) RNA enters 
the cytoplasm and is replicated to generate double stranded RNA intermediates and translated to generate viral proteins giving rise to new 
virus particles which can infect surrounding cells. As cells are lysed DAMPs are released. Intracellular innate immune receptors such as 
TLRs and RIG-1 recognize viral RNA and initiate signaling pathways activating transcription factors such as NFB, resulting in the 
production of inflammatory cytokines such as Interferons. DAMPs released from dying cells, PAMPs from virus particles and the 
cytokines released by infected cells activate pro-inflammatory pathways in immune cells such as neutrophils and macrophages in the 
lung. Complement cascade is also activated by virus particles. Activation of the NLRP3 inflammasome complex leads to activation and 
release of IL-1 and IL-18 by the activated cells, which acts in autocrine and paracrine manner to cause high level of cytokine and 
chemokine secretion, leading to ―cytokine storm‖. The cytokine storm initiates positive feedback loops leading to hyperactivation of 
immune cells such as PMN (polymorphonuclear leukocytes), M (macrophages), DC (dendritic cells), T lymphocytes and NK (natural 
killer) cells and a hyperinflammatory syndrome resulting in severe tissue injury 




cytokine release syndrome, and sepsis are not well 
characterized, and efforts to understand the multi-stage 
immunological process are required
12
. 
The progression of COVID-19 is marked by an 
early asymptomatic or mildly symptomatic stage with 
fever, dry cough, bodyache and fatigue and less 
frequently headache, productive cough and diarrhoea. 
Clinical symptoms include a decrease in the number 
of circulating lymphocytes to typically less than 1.0 × 
10
6
/mL. Transition to the severe stage is marked by 
dyspnea and hypoxia and is associated with abnormal 
lung CT scans showing typical ground glass opacities, 
increasing neutrophil counts and coagulopathies 
marked by increased prothrombin time and D-dimers. 
The severe stage is finally manifested by ARDS, 
caused by severe lung inflammation and damage, and 
is associated with increased levels of C-reactive 
protein (CRP), lactate dehydrogenase (LDH),  
D-dimer, ferritin, troponin, N-terminal pro-brain-type 
natriuretic peptide (NT-proBNP) and interleukin (IL)-6, 
all of which are markers for hyperinflammation and 
tissue damage (Table 1). At this stage patients suffer 
from respiratory failure, in spite of mechanical 
ventilation, with diffuse vasculopathy and multi-organ 
involvement which can ultimately lead to death
4,5,13–16
. 
The hyperinflammatory response in severely ill 
COVID-19 patients is marked by increased plasma 
levels of pro- and anti-inflammtory cytokines such as 
IL-6, IL-1b, IL-7, IL-8, IL-9, IL-10, IFN- and TNF-, 
chemokines such as MCP1, MIP1A and MIP1B which 
cause the migration of neutrophils, monocytes, T 
lymphocytes and NK cells to the lung alveoli and 
growth factors such as G-CSF and GM-CSF
4,6
. 
Elevated levels of IL-6 have been reported to have 
significant association with death in severe COVID-19 
cases, making Tocilizumab, the humanized monoclonal 
antibody against the IL-6 receptor, a possible treatment 
for severely ill COVID-19 patients
17
. These clinical 
parameters suggest that the immunologic profile of 
severe COVID-19 patients is similar to CRS and 
secondary hemophagocytic lymphohistiocytosis 




A detailed longitudinal study of cytokine profiles in 
COVID-19 patients with moderate and severe disease 
has exhibited a ―core COVID-19 signature‖ shared by 
both moderate and severe disease patients defined by  
IL-1, IL-1, IL-17A, IL-12 p70 and IFN
21
. Patients 
with severe disease are characterized by an additional 
inflammatory cluster consisting of thrombopoietin 
(TPO), IL-33, IL-16, IL-21, IL-23, IFNλ, eotaxin and 
eotaxin 3. Most of the patients with severe disease 
showed increased levels of the cytokines related to CRS, 
namely IL-1α, IL-1β, IL-6, IL-10, IL-18 and TNF. 
Longitudinal studies have shown that in the first ten days 
of symptom onset, both severe and moderate patients 
showed similar cytokine profiles, including the core 
COVID-19 signature. However, after ten days of 
symptom onset, these markers declined in patients with 
moderate disease but continued to remain elevated in 
patients with severe disease, together with emergence of 
additional cytokine markers, with an ultimately poor 
prognosis. 
 
Early stage of infection - Role of neutrophils and 
lymphocytes 
The hyperinflammatory response in COVID-19 is 
most likely primed by the multiple steps of the viral 
life cycle: virus entry, replication and cell lysis. 
SARS-CoV-2 entry into alveolar cells is mediated by 
the interaction of the S protein with the ACE2 
receptor protein which is expressed on many cell 
types including lung alveoli, nasal, oral, skin and 
kidney epithelial cells, smooth muscle cells and 
endothelial cells of vessels in the gastrointestinal tract 
as well as in arteries and veins
22
. The interaction of 
the S protein with ACE2 might perturb the renin-
angiotensin system, reducing the level of ACE2 and 
increasing the level of angiotensin II, and thereby 
affecting vascular homeostasis
23
. The role of ACE2 in 
vascular homeostasis is observed in ACE2 knockout 
mice, which when challenged with inflammatory 
insults showed increased vascular permeability, lung 
edema and neutrophil infiltration of lungs
24
. Similarly, 
infiltrating neutrophils and pro-inflammatory 
macrophages have been found in bronchoalveolar 
Table 1 — Threshold levels of some inflammatory markers with 
diagnostic and prognostic values in severe COVID-19 cases 
Inflammatory marker Threshold level in severe cases 
of COVID-19 
Interleukin-6 (IL-6) ≥ 80 pg/mL50 
Lactate dehydrogenase (LDH) ≥ 240 to 253.2 U/L51 
C-reactive protein (CRP) >26.9 mg/L52 
Ferritin >800 μg/L53 
D-dimer > 2.0 mg/L54 
N-terminal pro-brain-type 
natriuretic peptide  
(NT-proBNP) 
>900 pg/mL55 
The threshold values are indicative only, as they are calculated 
from meta-analysis of cumulated data from different reports or 
from large single centre studies 




lavage of severely ill COVID-19 patients
25
, and 
COVID-19 patients suffering from ARDS have been 
reported to develop neutrophilia (high number of 
neutrophils) and show the presence of toxic granules 
in neutrophils, suggesting the role of infiltrating 
neutrophils in lung inflammation and damage
4,14
. 
A gene network approach which constructed a 
protein-protein interaction network with upto 100 
proteins that directly interact with the seven putative 
SARS-CoV-2 receptors including ACE2 together with 
the peptidases DPP4 and ANPEP and pathogen-
binding proteins CD209, CLEC4G, CLEC4M and 
CEACAM1, followed by network inflation to allow 
mining of possible functional pathways showed 
―neutrophil degranulation‖ as the main Gene 
Ontology (GO) term in the expanded network
26
. There 
were 70 proteins in this category, including eight 
neutrophil-enriched genes, suggesting that SARS-
CoV-2 binding proteins, and the wider network of 
interacting proteins, may be directly involved in 
neutrophil activation and eliciting an inflammatory 
response. Neutrophils are involved in early antiviral 
immunity, but hyperactivation, degranulation and 
lysis can make them cytotoxic during severe 
pneumonia as observed in the case of other viral 
infections
27
. It is now clear that an increased 
peripheral neutrophil:lymphocyte ratio is observed in 
severe COVID-19 cases and is likely associated with 
an unfavourable prognosis
28
. Therefore the role of 
neutrophils in COVID-19 pneumonia and their 
possible importance as markers of disease progression 
and severity and also in therapeutic strategies require 
intense study.  
The role of lymphocytes in COVID-19 is less well 
understood. However, many studies have now shown 
that lymphonenia is significantly associated with 
disease severity in COVID-19 and can be an early and 
useful prognostic marker in determining the clinical 
course of the disease
28
. It has been suggested that the 
hyperinflammatory response is the key factor behind 
the lymphopenia, as serum levels of pro-inflammatory 
cytokines such as TNFa and IL-6 have been closely 
associated with decrease in circulating lymphocytes
28
. 
Massive lymphocyte death in lymphoid organs of 
deceased patients has been attributed to high levels of 
IL-6 and Fas-Fas ligand interactions. Exhaustion of T 





 T cells from COVID-19 
patients showing increased cell surface expression of 
programmed cell death protein 1 (PD1) and T cell 
immunoglobulin and mucin domain 3 (Tim-3), two 
well-known markers of T cell exhaustion
28
. Moreover, 
SARS-CoV-2 infection might also interfere with T 
cell expansion as genes involved in T cell activation and 
function such as MAP2K7 and SOS1 have been found 
to be downregulated in T cells of severe COVID-19 
patients
13
. Therefore, although lymphocytes, especially 
T cells, likely play a crucial role in the early immune 
response to SARS-CoV-2 infection, but subsequently 
undergo exhaustion and depletion most likely due to 
high cytokine levels, leading to lymphopenia and a high 





Viral replication and host immune dysregulation 
Post entry, replication of SARS-CoV-2 in host cells 
will lead to both single stranded and double stranded 
RNA intermediates, which will act as pathogen-
associated molecular patterns (PAMPs) and be 
recognized by the host innate immune sensors TLR7 
and TLR8 for ssRNA and TLR3, RIG-I and MDA5 
for dsRNA
30
. The activation of these immune sensors 
usually lead to activation of host antiviral immune 
defences, starting with the type 1 interferon (IFN) 
pathway
31
. Studies have shown that SARS-CoV-2 can 
evade this innate immune response by actively 
blocking the induction of Type 1 interferon pathway 
using ORF6, ORF8 and nucleocapsid proteins
32
. 
Thus, evasion of the host RNA-specific innate 
immune response at the beginning of the infection 
will lead to enhanced virus replication and increase in 
the number of infected cells
33
. Lung epithelial cells 
with actively replicating virus will eventually die, 
releasing damage-associated molecular patterns 
(DAMPs) such as ferritin and high-mobility group 
box 1 (HMGB1) or high levels of IL-1 and IL-6 
through NALRP3 inflammosome activation
34,35
, 
which will be recognized by resident immune cells 
such as alveolar macrophages and infiltrating 
neutrophils. This will further amplify the inflammatory 
response and lead to cytokine release through autocrine 
loops of activation. Therefore modulation of the initial 
innate immune response activated by PAMPs and a 
secondary, amplified response mediated by DAMPs 
leads to a hyperinflammatory response to SARS-CoV-2 
infection in lungs. This is further induced by the 
dysregulation of the complement system, as excessive 
activation of complement system components such as 
C3, C3a, C5, C5a and MASP2 has been associated 
with increased inflammation in SARS-CoV-2 
infections
36,37
. This can activate alveolar macrophages 




leading to release of IL-6 and other pro-inflammatory 
cytokines, further exacerbating the inflammation and 
lung damage. 
 
Severe stage of disease - Hyperinflammation and 
acute respiratory distress syndrome 
The progression to the severe stage of the disease 
could therefore be marked by this hyperinflammatory 
response induced by increased levels of IL-1 and  
IL-6 and DAMPS which will activate innate immune 
cells expressing IL-1R such as macrophages and NK 
cells. These will amplify the inflammation with 
release of pro-inflammatory cytokines IL-6, IL-18, 
TNF and IL-1 by macrophages and IFN- by NK 
cells, which will act in a positive feedback manner to 
further enhance the inflammatory response, ultimately 
leading to a ―cytokine storm‖. High levels of IL-6 and 
IFN-, found in the plasma of severely ill COVID-19 
patients, are hallmarks of cytokine storm
20
. Increased 
level of IFN-is a hallmark of sHLH, as it activates 
monocytes and macrophages as also seen in severe 
COVID-19 cases
38
. IL-6 contributes to severe CRS by 
enhancing vascular permeability and further 
infiltration of inflammatory cells
17
. IL-1b and TNF 
has been shown to increase the levels of hyaluronan 
synthase 2 and consequently the level of hyaluronic 
acid (HA). HA, which can absorb high quantities of 
water, may contribute to the accumulation of fluids in 
the alveoli of COVID-19 patients, further affecting 
respiratory function
39,40
. These events will create a 
cytokine and chemokine-mediated hyperinflammatory 
environment in the lung epithelium which can recruit 
and hyperactive T cells, that can further exacerbate 
inflammatory damage of the tissue. The exhaustion of 
T cells and NK cells, observed in severe COVID-19 
cases, might be subsequent to this hyperactivation
29
. 
Hypractivation and subsequent exhaustion of T cells 
in progressive COVID-19 disease may also be 
associated by the decrease in CD4+ TReg cells, which 
play a key role in controlling hyperinflammation and 
protection from tissue damage
41
. Together, these 
immunological and physiological events lead to 
extensive diffuse alveolar damage, including 
desquamation of alveolar cells, hyaline membrane 
formation and pulmonary oedema, most likely 
independent of and secondary to the viral infection, 
leading to ARDS in severe COVID-19 patients
6
. 
The hyperinflammatory response in ARDS may 
also give rise to a pro-fibrotic condition in the lungs 
of severely ill COVID-19 patients, with major 
implications for treatment both during ARDS and in 
the long term for survivors of COVID-19
42
. Indeed, 
autopsy of 159 patients with ARDS has shown a high 
correlation of lung fibrosis with the duration of 
ARDS, suggesting that to be effective, potential 
antifibrotic therapy should be considered early in 
ARDS onset
43
. Dysregulation of multiple pathways 
during the hyperinflammatory response can lead to 
the pro-fibrotic condition, including the release of 
fibrotic mediators such as matrix metalloproteases 
which causes epithelial and endothelial injury and 
proliferation of fibroblasts. Inflammation leads to the 
activation of profibrotic pathways regulated by TGF 
and vascular dysfunction
44
, mediated by VEGF and 
cytokines such as IL-1 and IL-6, can lead to fibrosis 
from ARDS
45,46
, marked by the accumulation of 
fibroblasts and myofibroblasts and the excessive 
deposition of collagen and other components of the 
extracellular matrix. Recognition of this pro-fibrotic 
condition might help in deciding therapeutic strategies 
for treating severe COVID-19 and preventing the 




Targeting hyperinflammation for therapy in 
COVID-19 
The recognition of a hyperinflammatory syndrome as 
the cause of morbidity and mortality in a large number of 
severely ill COVID-19 patients has led to the 
consideration of a number of anti-inflammatory and 
immunosuppressive agents as potential therapeutics for 
COVID-19. Clinical trials are ongoing for multiple 
agents including complement inhibitors (eculizumab), 
recombinant human anti human IL-1β mAb 
(canakinumab), human IL-1R antagonist (anakinra), anti 
human IL-6 receptor mAb (tocilizumab and sarilumab), 
anti human IFN mAb (emapalumab), inhibitor of 
JAK1/2 pathway (ruxolitinib), human anti IL-17A mAb 
(secukinumab and ixekizumab) and others
1
. Treatment 
with the IL-6 inhibitor tocilizumab appears to show 
reduction in mortality in some retrospective studies, and 
has been approved for emergency usage by various 
countries, although results from randomized, controlled 
trials are still awaited. Anti-inflammatory glucocorticoids 
such as methylprednisolone may reduce the risk of death 
among severe COVID-19 patients with ARDS but are 
not recommended during early stage of viral infection as 
they may inhibit the antiviral immunity and affect virus 
clearance
19,48
. Hyaluronidase, the enzyme that catalyzes 
the degradation of hyaluronic acid and hymecromone, an 
inhibitor of hyaluronic acid synthetase are being 
considered as agents to decrease elevated hyaluronic acid 
and thereby relieve respiratory distress and lung damage 




by decreasing fluid accumulation and reduce pulmonary 
edema
39
. Finally, anti-fibrotic agents with anti-
inflammatory functions such as pirfenidone and the 
receptor tyrosine kinase inhibitor nintedanib are being 
considered to retard or reduce the pulmonary fibrosis 
associated with hyperinflammation
42
. Although these 
anti-inflammatory and immunoregulatory agents 
constitute important options in the therapeutic strategies 
against COVID-19, their usage translates into a tight-
rope walk for clinicians treating COVID-19 patients as 
possible immunosuppression by these agents can 
negatively affect effective antiviral response, and may 
also fail to combat secondary bacterial infections with 
multidrug resistant bacterial strains which are a common 
feature, especially of intensive care setups
49
. A closer 
synergy between clinicians, intensivists and scientists, 
especially virologists and inflammation biologists, is 
therefore required for understanding the molecular and 
cellular basis of disease progression, and developing and 
implementing effective therapies against COVID-19. 
 
Conclusion 
Severe cases of COVID-19 are marked by an excessive 
and uncontrolled inflammatory response that 
exacerbates lung damage caused by viral infection, and 
contributes to acute respiratory distress syndrome and 
respiratory failure. This hyperinflammatory syndrome is 
characterized by multiple cellular and molecular events 
which results in lung damage ultimately leading to 
respiratory failure.The molecular and cellular mediators 
and markers for this hyperinflammatory syndrome are 
therefore important diagnostic, prognostic and 
therapeutic targets in COVID-19. 
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